Zhengzhou Yicen Trading Co., Ltd. – Trademark Portfolio
Entity Type: 99
Zhengzhou Yicen Trading Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 14 (Jewelry) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include FEZZET and BILAEUO. The owner is based in Zhengzhou, Henan.
Room 1401, Unit 1, Building 2
No. 346, Wenhua North Road, Huiji Dist.
Zhengzhou, Henan 450053 , CN
Showing of trademarks Trademarks
Trademark Classifications
Zhengzhou Yicen Trading Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Precious metals and their alloys; jewellery, precious stones; horological instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Zhengzhou Yicen Trading Co., Ltd. have?
Zhengzhou Yicen Trading Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Zhengzhou Yicen Trading Co., Ltd. file in?
Zhengzhou Yicen Trading Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 14 (Jewelry), Class 5 (Pharmaceuticals). Class 14 covers precious metals and their alloys; jewellery, precious stones; horological instruments.
What are Zhengzhou Yicen Trading Co., Ltd.'s most well-known trademarks?
Zhengzhou Yicen Trading Co., Ltd.'s registered trademark portfolio includes well-known marks such as FEZZET and BILAEUO. These are among 2 currently registered trademarks in the portfolio.
What is Zhengzhou Yicen Trading Co., Ltd.'s trademark registration success rate?
Zhengzhou Yicen Trading Co., Ltd. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.